A model for the emergence of drug resistance in the presence of asymptomatic infections

Mathematical Biosciences

Volumn 243, Issue 2, 2013, Pages 163-177

  Robinson, Marguerite ^a,c   Stilianakis, Nikolaos I ^a,b  

^a JOINT RESEARCH CENTRE   (Italy)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c Climate Dynamics and Impacts Unit Institut Català de Ciències del Clima IC3   (Spain)

Author keywords

Asymptomatic; Drug resistance; Influenza; Treatment

Indexed keywords

ASYMPTOMATIC; ASYMPTOMATIC INFECTION; BASIC REPRODUCTION NUMBER; DISEASE-FREE EQUILIBRIUM; DRUG RESISTANCE; DRUG-RESISTANT STRAINS; INFLUENZA; TREATMENT;

MATHEMATICAL MODELS; STRAIN;

DISEASE CONTROL;

DISEASE TREATMENT; DRUG RESISTANCE; EPIDEMIC; INFLUENZA; NUMERICAL MODEL; PATHOGEN;

ANTIBIOTIC RESISTANCE; ANTIVIRAL RESISTANCE; ARTICLE; ASYMPTOMATIC INFECTION; BACTERIAL STRAIN; BACTERIAL TRANSMISSION; BASIC REPRODUCTION NUMBER; HOMEOSTASIS; HUMAN; INFLUENZA; INTERMETHOD COMPARISON; MATHEMATICAL ANALYSIS; MATHEMATICAL MODEL; MENINGITIS; STAPHYLOCOCCUS INFECTION; VIRUS STRAIN; VIRUS TRANSMISSION;

ASYMPTOMATIC INFECTIONS; DRUG RESISTANCE; EPIDEMICS; HUMANS; INFECTION; MODELS, STATISTICAL;

EID: 84876853130     PISSN: 00255564     EISSN: 18793134     Source Type: Journal    
DOI: 10.1016/j.mbs.2013.03.003     Document Type: Article

References (49)

1. Fraser C., Riley S., Anderson R.M., Ferguson N.M. Factors that make an infectious disease outbreak controllable. PNAS 2004, 101:6146.
2. Mathews J.D., McCaw C.T., McVernon J., McBryde E.S., McCaw J.M. A biological model for influenza transmission: pandemic planning implications of asymptomatic infection and immunity. PLoS ONE 2007, 2:e1220.
3. st century. BMC Public Health 2011, 11:78.
4. Longini I.M., Halloran M.E., Nizam A., Yang Y. Containing pandemic influenza with antiviral agents. Am. J. Epidemiol. 2004, 159:623.
5. Arino J., Brauer F., van den Driessche P., Watmough J., Wu J. A model for influenza vaccination and antiviral treatment. J. Theor. Biol. 2008, 253:118.
6. McCaw J.M., Wood L.G., McCaw C.T., McVernon J. Impact of emerging antiviral drug resistance on influenza containment and spread: influence of subclinical infection and strategic use of a stockpile containing one or two drugs. PLoS ONE 2008, 3:e2362.
7. Stilianakis N.I., Perelson A.S., Hayden F.G. Emergence of drug resistance during an influenza epidemic: insights from a mathematical model. J. Infect. Dis. 1998, 177:863.
8. Regoes R.R., Bonhoeffer S. Emergence of drug-resistant influenza virus: population dynamical considerations. Science 2006, 312:380.
9. Débarre F., Bonhoeffer S., Regoes R.R. The effect of population structure on the emergence of drug resistance during influenza pandemics. J.R. Soc. Interface 2007, 4:893.
10. Wu J.T., Riley S., Fraser C., Leung G.M. Reducing the impact of the next influenza pandemic using household-based public health interventions. PLoS Med. 2006, 3:1532.
11. Moghadas S.M., Bowman C.S., Röst G., Wu J. Population-wide emergence of antiviral resistance during pandemic influenza. PLoS ONE 2008, 3:e1839.
12. Alexander M.E., Bowman C.S., Feng Z., Gardam M., Moghadas S.M., Röst G., Wu J., Yan P. Emergence of drug resistance: implications for antiviral control of pandemic influenza. Proc. R. Soc. B 2007, 274:1675.
13. Keeling M., Rohani P. Modelling Infectious Diseases in Humans and Animals 2008, Princeton University Press.
14. Kemper J.T. The effects of asymptomatic attacks on the spread of infectious disease: a deterministic model. Bull. Math. Biol. 1978, 40:707.
15. Anderson R.M., May R.M. Infectious Diseases of Humans: Dynamics and Control 1991, Oxford University Press.
16. van den Driessche P., Watmough J. Further notes on the basic reproductive number. Mathematical Epidemiology 2008, 159. Springer, New York.
17. van den Driessche P., Watmough J. Reproduction numbers and sub-threshold endemic equilibria for compartmental models of disease transmission. Math. BioSci. 2001, 180:29.
18. Diekmann O., Heesterbeek J.A.P. Mathematical Epidemiology of Infectious Diseases: Model Building, Analysis and Interpretation 2000, Wiley, Chichester, UK.
19. Diekmann O., Heesterbeek J.A.P., Roberts M.G. The construction of next-generation matrices for compartmental epidemic models. J. R. Soc. Interface 2010, 7:873.
20. Gu Y., Komiya N., Kamiya H., Yasuo Y., Taniguchi K., Okabe N. Pandemic (H1N1) 2009 transmission during presymptomatic phase, Japan. Emerg. Infect. Dis. 2011, 17:1737.
21. P. Marquez, D. Tereshita, L. Engish, Pre-symptomatic health care worker transmission of pandemic (H1N1) 2009 influenza in acute care settings, Acute Communicable Disease Control Program, Los Angeles, California, Special Studies Report, 2009, Los Angeles County Department of Public Health. http://www.ph.lacounty.gov/acd/reports/annual/2009SpecialStudies.pdf.
22. Lau L.H.L., Cowling B.J., Fang V.J., Chan K.H., Lau E.H.Y., Lipsitch M., Cheng C.K.Y., Nouck P.M., Uyeki T.M., Peiris J.S.M., Leung G.M. Viral shedding and clinical illness in naturally acquired influenza virus infections. J. Infect. Dis. 2010, 201:1509.
23. Sheat K. An investigation into an explosive outbreak of influenza - New Plymouth. Commun. Dis. N. Z. 1992, 92:18.
24. Webb G.F., Hsieh Y.-H., Wu J., Blaser M.J. Pre-symptomatic influenza transmission surveillance and school closings: implications for novel influenza A (H1N1). Math. Model. Nat. Phenom. 2010, 5:191.
25. World Health Organisation Writing Group Nonpharmaceutical interventions for pandemic influenza, international measures. Emerg. Infect. Dis. 2006, 12:81.
26. Ferguson N.M., Mallett S., Jackson H., Roberts N., Ward P. A population-dynamic model for evaluating the potential spread of resistant influenza virus infections during community-based use of antivirals. J. Antimicrob. Chemother. 2003, 51:977.
27. Patrozou E., Mermel L.A. Does infuenza transmission occur from asymptomatic infection or prior to symptom onset?. Public Health Rep. 2009, 124:193.
28. Donnelly C.A., Finelli L., Cauchemez S., et al. Serial intervals and the temporal distribution of secondary infections within households of 2009 pandemic influenza A (H1N1): implications for influenza control recommendations. Clin. Infect. Dis. 2011, 52(S1):S123.
29. Elvebeack L.R., Fox J.P., Ackerman E., Langworthy A., Boyd M., Gatewood L. An influenza simulation model for immunization studies. Am. J. Epidemiol. 1976, 103:152.
30. Carrat F., Vergu E., Ferguson N.M., Lemaitre M., Cauchemez S., Leach S., Valleron A.J. Time lines of infection and disease in human influenza: a review of volunteer challenge studies. Am. J. Epidemiol. 2008, 167:775.
31. Ghani A.C., Baguelin M., Griffin J., et al. The early transmission dynamics of H1N1pdm influenza in the United Kingdom. PLoS Curr. Influenza 2009, RRN1130.
32. Mills C.E., Robins J.M., Lipsitch M. Transmissibility of 1918 pandemic influenza. Nature 2004, 432:904.
33. Boëlle P.Y., Ansart S., Cori A., Vallerona A.J. Transmission parameters of the A/H1N1 (2009) influenza virus pandemic: a review. Influenza Other Respir. Viruses 2011, 5:306.
34. Ferguson N.M., Mallett S., Jackson H., Roberts N., Ward P. A population-dynamic model for evaluating the potential spread of drug-resistant influenza virus infections during community-based use of antivirals. J. Antimicrob. Chemother. 2003, 51:977.
35. Nichol K.L., Tummers K., Hoyer-Leitzel A., Marsh J., Moynihan M., McKelvey S. Modeling seasonal influenza outbreak in a closed college campus: impact of pre-season vaccination in-season vaccination and holidays/breaks. PLoS ONE 2010, 5:e9548.
36. Yang Y., Sugimoto J.D., Halloran M.E., Basta N.E., Chao D.L., Matrajt L., Potter G., Kenah E., Longini I.M. The transmissibility and control of pandemic influenza A (H1N1) virus. Science 2009, 326:729.
37. Chowell G., Miller M.A., Viboud C. Seasonal influenza in the United States France and Australia: transmission and prospects for control. Epidemiol. Infect. 2008, 136:852.
38. Dushoff J., Plotkin J.B., Levin S.A., Earn D.J.D. Dynamical resonance can account for seasonality of influenza epidemics. PNAS 2004, 101:16915.
39. Van Voris L.P., Betts R.F., Hayden F.G., Christmas W.A., Douglas Jr R.F. Successful treatment of naturally occurring influenza A/USSR/77 H1N1. JAMA 1981, 245:1128.
40. Couch R.B., Kasel J.A., Glezen W.P., Cate T.R., Six H.R., Taber L.H., Frank A.L., Greenberg S.B., Zahradnik J.M., Keitel W.A. Influenza: its control in person and populations. J. Infect. Dis. 1986, 153:431.
41. Hurt A.C., Deng Y.M., Ernest J., Caldwell N., Leang L., Iannello P., Komadina N., Shaw R., Smith D., Dwyer D.E., Tramontana A.R., Lin R.T., Freeman K., Kelso A., Barr I.G. Oseltamivir-resistant influenza viruses circulating during the first year of the influenza A(H1N1) 2009 pandemic in the Asia-Pacific region, March 2009 to March 2010. Euro Surveill 2011, 16(3):19770.
42. Stephenson I., Democratis J., Lackenby A., McNally T., Smith J., Pareek M., Ellis J., Bermingham A., Nicholson K., Zambon M. Neuraminidase inhibitor resistance after oseltamivir treatment of acute influenza A and B in children. Clin. Infect. Dis. 2009, 4:389.
43. Lackenby A., Gilad J.M., Pebody R., Miah S., Calatayud L., Bolotin S., Vipond I., Muir P., Guiver M., McMenamin J., Reynolds A., Moore C., Gunson R., Thompson C.I., Galiano M., Bermingham A., Ellis J., Zambon M. Continued emergence and changing epidemiology of oseltamivir-resistant influenza A(H1N1) 2009 virus, United Kingdom, winter 2010/11. Euro Surveill 2011, 5:19784.
44. Castillo-Chavez C., Feng Z. To treat or not to treat: the case of tuberculosis. J. Math. Biol. 1997, 35:629.
45. Feng Z., Iannelli M., Milner F.A. A two-strain tuberculosis model with age of infection. SIAM J. Appl. Math. 2002, 62:1634.
46. Castillo-Chavez C., Song B. Dynamical models of tuberculosis and their applications. Math. BioSci. Eng. 2004, 1:361.
47. Balicer R.D., Huerta M., Davidovitch N., Grotto I. Cost-benefit of stockpiling drugs for influenza pandemic. Emerg. Infect. Dis. 2005, 11:1280.
48. Lugner A.K., Postma M.J. Investment decisions in influenza pandemic contingency planning: cost-effectiveness of stockpiling antiviral drugs. Eur. J. Public Health 2009, 19:516.
49. Arino J., Bowman C.S., Moghadas S.M. Antiviral resistance during pandemic influenza: implication for stockpiling and drug use. BMC Infect. Dis. 2009, 9:8.